Archives: Speakers

Energetic, hands-on leader, with broad experiences bridging IVD Product Development/commercialization and Clinical Trial design, operation and registrational activities. Successful commercial tests include CytoScan™ XON (Exon level CN detection), CytoScan™ Optima (Prenatal CN detection), Cytoscan® Dx (first-to-market FDA approved whole genome CN assay). Experienced in the entire product life-cycle with strong command of R&D, Manufacturing and Clinical Validation. Successful in balancing internal and external stake-holders and tying strategic goals with tactical execution. Passionate about people, teams and a culture of innovation. Experienced in : US and CE-IVD registrations, Observational Trials, Clinical Trial Management, LDT/IVD Product Development, Design Control/documentations, analytical and clinical validation, Commercialization, GLP, GCP, GMP compliance, Manufacturing Transfer, Reagent Development/Kitting , Laboratory Operations, Lead Internal/External collaborations, Technology Assessment/IP generation, Design of Experiments (DOE), Microarray analysis, Sequencing, Cell-free DNA analysis.

Experienced analytical professional with a versatile background in the biotechnology industry and clinical research site. Skilled in project management, quality compliance, protocol development, site management, clinical pharmacology and clinical trials in autoimmune, allergy, cardiovascular, nephrology, neuromuscular, pain and pediatrics.

Shreya Badhrinarayanan, MD, FRSPH, is the Global Development Lead for Clinical Development, Oncology & Hematology at Pfizer. She leads clinical programs advancing antibody-drug conjugates (ADCs), bispecific antibodies, small molecules, and immuno-oncology (IO) biologics, driving innovative treatments in cancer care. Previously at Genentech, a Roche subsidiary, she provided strategic direction for the development of new Immuno-Oncology drugs by leading cross-functional teams and conducting medical monitoring of clinical trials. Earlier in her career, she served as a Physician with the National Health Service (NHS) in the UK, where she made significant contributions to clinical and research initiatives. Thriving in the field of medical leadership and management, Dr. Badhrinarayanan received the Edward Jenner Award from the NHS Leadership Academy. To further her passion for teaching, she served as an Honorary Lecturer in Medical Education and Simulation at the University of Adelaide Medical School, Australia. Her wide range of interests varies from AI in health care to D&I initiatives that have been embodied through her contributions to print and media as well as at conferences across the globe. In addition, she is the editor/reviewer of numerous high-impact journals, including the British Medical Journal. For her work and commitment towards public health, Dr. Badhrinarayanan was elected as a Fellow of the Royal Society of Public Health, UK. She received her medical degree from University of Sussex Medical School, UK, with numerous accolades.

Craig Ellison, Partner Sales Leader, Workday

Craig Ellison is a Partner Sales Leader at Workday, supporting customers and partners across the UK. In his role, he focuses on building strategic relationships, aligning Workday solutions to real business outcomes, and ensuring joint go-to-market initiatives deliver tangible value and long-term success for clients.

Wafaa is a Senior Analyst in the Strategic Intelligence Pharma team at GlobalData’s London office. She specializes in delivering in-depth analysis and reports on key pharmaceutical industry themes, with a focus on advanced technologies such as Digital Health, AI, and Big Data. Her work also includes producing detailed digital marketing insights across a range of therapeutic areas, including oncology, neurology, and immunology. Prior to this role, she worked in GlobalData’s Technology Strategic Intelligence team, where she contributed both quantitative and qualitative analysis of disruptive trends and technologies across different sectors. She holds a BSc degree in Biomedical Engineering and an MSc in Healthcare Management from City, University of London

Christina Meier joined Vontobel in September 2021 as a Senior Offering & Project Manager, where she is responsible for developing and advancing new products and services within Private Clients. In addition, she co-leads the NextGen Investors Program, aimed at engaging the next generation of clients and facilitating wealth transitions across generations. Prior to joining Vontobel, Christina worked in strategy and business development at an international law firm in Zurich and held roles at Credit Suisse in compliance strategy and regulatory projects. Christina began her professional journey at EY in Risk Consulting, where she gained experience in managing complex challenges and crafting strategic solutions. She holds a Bachelor of Science in Banking & Finance and a Master of Science in Entrepreneurship & Finance from the University of Liechtenstein, as well as a CAS in Compliance in Financial Services from the University of St. Gallen.

Christina Kahr joined Vontobel in January 2024. As a Senior Offering & Project Manager, she is responsible for driving initiatives targeting the development of products and services within Private Clients. Additionally, Christina co-leads the NextGen Investors Program, an initiative dedicated to empowering the next generations of investors and fostering multi-generational wealth management. Before joining Vontobel, Christina gained valuable experience at UBS, where she was responsible for the management of discretionary investment products. Prior to that, she led strategy and compliance-related projects at Credit Suisse, further strengthening her expertise in the financial services industry. Christina holds a Master of Science in Banking & Finance from the Lucerne University of Applied Sciences and a Bachelor of Science in Business Administration from the Vienna University of Economics and Business.